Loading...
•
Dec 31, 2025
Twist Bioscience Q1 2026 Earnings Report
Reported record quarterly revenue with margin expansion and a narrower net loss.
Key Takeaways
Twist Bioscience delivered record Q1 revenue growth, expanded gross margin above 50%, and reduced net loss year over year while reaffirming its path toward adjusted EBITDA breakeven.
Record quarterly revenue exceeded guidance
Gross margin expanded meaningfully year over year
Net loss narrowed compared to the prior year
Company reiterated adjusted EBITDA breakeven target
Revenue by Segment
Forward Guidance
The company raised full-year revenue guidance and reiterated its expectation to reach adjusted EBITDA breakeven in Q4 FY26.
Positive Outlook
- Full-year revenue guidance increased
- Gross margin expected to remain above 52%
- Sequential revenue growth expected in Q2
- Continued momentum in core segments
- Clear timeline toward profitability
Challenges Ahead
- Adjusted EBITDA breakeven not expected until Q4
- Continued operating losses in the near term
- Dependence on sustained revenue growth
- Ongoing cost pressures from operations
- Exposure to market and demand variability
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...